Literature DB >> 4762235

The possible role of metabolites in therapeutic response to chlorpromazine treatment.

G Sakalis, T L Chan, S Gershon, S Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4762235     DOI： 10.1007/bf00422150

Source DB:  PubMed          Journal:  Psychopharmacologia


× No keyword cloud information.
  16 in total

Review 1.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

5.  Predictive indices for chlorpromazine therapy in schizophrenics.

Authors:  P A Dixon; E Oforah; R Makanjuola
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics.

Authors:  A V Mackay; A F Healey; J Baker
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

7.  Clinical pharmacokinetic studies of perphenazine.

Authors:  C Eggert Hansen; T Rosted Christensen; J Elley; L Bolvig Hansen; P Kragh-Sorensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 8.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

9.  Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.

Authors:  S Loga; S Curry; M Lader
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

10.  Phase I metabolism of imipramine by microsomes of small intestine in comparison with metabolism by liver microsomes.

Authors:  W Christ; W Hecker; H Junge; G Stille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.